Metformin has been reported to enhance immunotherapy via multiple effects on the tumor immune microenvironment, including protection of CD8+ T cells from apoptosis, depletion of PD-L1, and reduction of intratumoral hypoxia, together preserving anti-tumor immune cell functionality and reversing an immunosuppressive TME [100]. The gene discussed is CD274; the disease is neoplasm.